Accuray Inc (Accuray) is a radiation oncology company that manufactures, develops, and sells treatment solutions for advanced treatments such as stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), image-guided radiation therapy (IGRT), and adaptive radiation therapy.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Accuray’s R&D initiatives focus on continued innovation to ensure future success. The company's current product development activities include projects aimed at expanding clinical applications, driving product differentiation, and improving the usability, interoperability, reliability, and performance of its products. Accuray is committed to developing innovative technologies to enhance its products and increase sales. The company's research activities are designed to enable new product development opportunities by advancing existing core technologies such as next-generation linear accelerators, adaptive therapy, patient imaging, motion management, and treatment planning capabilities. The modular design of the company’s systems supports rapid development for new clinical capabilities and performance enhancements. The company collaborates with research programs at hospitals, cancer treatment centers, academic institutions, and research institutions worldwide, often involving milestone-based payments and up-front funding. The company’s R&D units are located in Sunnyvale and Santa Clara, California, where the company conducts product research and development and administrative functions. These units are responsible for managing the company's R&D activities, including developing new technologies and improving existing products. Accuray also works with suppliers to develop new components and seeks opportunities to acquire or invest in external research. The company has entered into collaboration agreements with industrial partners in radiation oncology and medical imaging to accelerate innovation and bring complementary products and technologies to market. In FY2025, the company spent US$47.9 million on its R&D activities, which as a percentage of revenue stood at 10.4%.